| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE37314 | IPR | Pyrimidine derivatives |
Jan, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE37314 (Pediatric) | IPR | Pyrimidine derivatives |
Jul, 2016
(7 years ago) | |
| US7030152 | IPR | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr, 2018
(6 years ago) | |
| US7964614 | IPR | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr, 2018
(6 years ago) | |
|
US7030152 (Pediatric) | IPR | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct, 2018
(5 years ago) | |
|
US7964614 (Pediatric) | IPR | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct, 2018
(5 years ago) | |
| US6316460 | IPR | Pharmaceutical compositions |
Aug, 2020
(3 years ago) | |
|
US6316460 (Pediatric) | IPR | Pharmaceutical compositions |
Feb, 2021
(3 years ago) | |
| US6858618 | IPR | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Dec, 2021
(2 years ago) | |
|
US6858618 (Pediatric) | IPR | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Jun, 2022
(1 year, 10 months ago) | |
Crestor is owned by Ipr.
Crestor contains Rosuvastatin Calcium.
Crestor has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Crestor are:
- USRE37314*PED
- US7030152
- US7964614
- US7030152*PED
- US7964614*PED
- US6316460
- US6316460*PED
- US6858618
- US6858618*PED
- USRE37314
Crestor was authorised for market use on 12 August, 2003.
Crestor is available in tablet;oral dosage forms.
Crestor can be used as use of rosuvastatin calcium to reduce elevated total-c, ldl-c, apob, nonhdl-c or tg levels; to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia; and to slow the progression of atherosclerosis., use of rosuvastatin calcium for the primary prevention of cardiovascular disease in individuals without clinically evident coronary heart disease but with increased risk factors.
The generics of Crestor are possible to be released after 27 May, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-573) | Nov 06, 2011 |
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| New Indication(I-732) | May 27, 2019 |
| New Patient Population(NPP) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE-118) | May 27, 2023 |
| New Indication(I-621) | Feb 08, 2013 |
| New Indication(I-611) | Oct 16, 2012 |
| Pediatric Exclusivity(PED) | Apr 16, 2013 |
Drugs and Companies using ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 12 August, 2003
Treatment: Use of rosuvastatin calcium for the primary prevention of cardiovascular disease in individuals without clinically evident coronary heart disease but with increased risk factors; Use of rosuvastatin c...
Dosage: TABLET;ORAL
CRESTOR family patents
